In the latter report, the cannabinoid receptor 2 (CB2) agonist lenabasum (Figure 1), a 9-carbon 1,1-dimethylheptyl side-chain analogue of the tetrahydrocannabinol (THC) metabolite THC-11-oic acid (also known as JBT-101, ajulemic acid, formerly anabasum), was discovered as a potential treatment for dermatomyositis, which has since been designated as an orphan drug by the European Medicines Agency (EMA) [9]. The gene discussed is CNR2; the disease is dermatomyositis.